Vanguard Group Inc. Purchases 3,911,404 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

Vanguard Group Inc. raised its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 397.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,896,185 shares of the company's stock after acquiring an additional 3,911,404 shares during the period. Vanguard Group Inc. owned about 0.59% of Dr. Reddy's Laboratories worth $77,311,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. LPL Financial LLC raised its stake in shares of Dr. Reddy's Laboratories by 418.7% during the 4th quarter. LPL Financial LLC now owns 128,126 shares of the company's stock worth $2,023,000 after purchasing an additional 103,424 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Dr. Reddy's Laboratories in the 4th quarter worth approximately $95,000. Marietta Investment Partners LLC raised its holdings in shares of Dr. Reddy's Laboratories by 234.6% in the 4th quarter. Marietta Investment Partners LLC now owns 17,300 shares of the company's stock valued at $273,000 after acquiring an additional 12,130 shares in the last quarter. Sei Investments Co. lifted its position in Dr. Reddy's Laboratories by 399.2% during the fourth quarter. Sei Investments Co. now owns 82,625 shares of the company's stock valued at $1,305,000 after purchasing an additional 66,072 shares during the last quarter. Finally, American Century Companies Inc. grew its position in Dr. Reddy's Laboratories by 418.1% in the fourth quarter. American Century Companies Inc. now owns 862,365 shares of the company's stock worth $13,617,000 after acquiring an additional 695,932 shares in the last quarter. Hedge funds and other institutional investors own 3.85% of the company's stock.

Analyst Ratings Changes

Separately, Nomura cut Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th.

Dr. Reddy's Laboratories Stock Performance

RDY stock traded up $0.02 on Wednesday, hitting $13.34. The company had a trading volume of 107,720 shares, compared to its average volume of 1,407,602. The stock has a market cap of $11.13 billion, a price-to-earnings ratio of 21.23 and a beta of 0.51. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The stock's 50-day simple moving average is $13.17 and its 200 day simple moving average is $14.33. Dr. Reddy's Laboratories Limited has a 12-month low of $12.26 and a 12-month high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, equities research analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.